MIRA Pharmaceuticals reports positive preclinical results for MIRA-55 oral formulation for chronic pain

MIRA PHARMACEUTICALS, INC.

Selected lead oral formulation of MIRA-55 with favorable oral bioavailability and sustained systemic exposure.
Formulation demonstrated reproducible distribution into brain and liver tissue after oral administration.
Prior studies showed oral MIRA-55 normalized pain and reduced inflammation, outperforming injected morphine.
MIRA-55 exhibited anxiolytic activity and no THC-like CNS effects; interacts with cannabinoid system distinct from THC.
Company plans further preclinical evaluation of tissue exposure, pharmacodynamic activity, and therapeutic efficacy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.